Clinical Scorecard: FDA raises TMB threshold for pembrolizumab
At a Glance
| Category | Detail |
|---|---|
| Condition | Previously treated unresectable or metastatic TMB-high solid tumors |
| Key Mechanisms | The FDA raised the tumor mutational burden threshold for the indication from 10 to 13 mutations per megabase because efficacy supporting traditional approval was not confirmed at levels from 10 to less than 13 mutations per megabase. |
| Target Population | Adults and pediatric patients with unresectable or metastatic TMB-high solid tumors that progressed after prior treatment and for whom no satisfactory alternative treatment options exist; TMB must be determined using an FDA-authorized test. |
| Care Setting | Treatment of previously treated advanced solid tumors with intravenous pembrolizumab or the subcutaneous pembrolizumab/berahyaluronidase alfa-pmph formulation, according to the applicable prescribing information. |
Key Highlights
- The FDA converted the indication from accelerated to traditional approval and raised the TMB threshold from 10 to at least 13 mutations per megabase.
- The decision was supported by KEYNOTE-158, a multicohort, nonrandomized phase 2 trial without a randomized comparator.
- Among 220 patients with TMB levels of at least 13 mutations per megabase, the objective response rate was 36%; 58% of responders maintained response for at least 12 months.
- The FDA reported that the safety profile remained consistent with that previously established for pembrolizumab monotherapy.
Guideline-Based Recommendations
Diagnosis
- Determine TMB status using an FDA-authorized test.
- The indication applies to TMB-high tumors with at least 13 mutations per megabase.
Management
- The indication is for adults and pediatric patients with unresectable or metastatic solid tumors that progressed following prior treatment and for whom no satisfactory alternative treatment options exist.
- For intravenous pembrolizumab, the recommended adult dose is 200 mg every 3 weeks or 400 mg every 6 weeks; the pediatric dose is 2 mg/kg every 3 weeks, up to 200 mg per dose.
- Continue treatment until disease progression, unacceptable toxicity, or a maximum of 24 months. Consult separate prescribing information for subcutaneous pembrolizumab/berahyaluronidase alfa-pmph dosing.
Monitoring & Follow-up
- Assess for disease progression and unacceptable toxicity during treatment.
Risks
- Prescribing information warns of immune-mediated adverse reactions, infusion-related reactions, complications following allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicity.
Patient & Prescribing Data
Adults and pediatric patients with unresectable or metastatic TMB-high solid tumors that have progressed after prior treatment, with no satisfactory alternative treatment options, and TMB of at least 13 mutations per megabase determined by an FDA-authorized test.
Intravenous dosing is 200 mg every 3 weeks or 400 mg every 6 weeks for adults, and 2 mg/kg every 3 weeks up to 200 mg per dose for pediatric patients. Treatment is limited to disease progression, unacceptable toxicity, or 24 months. Subcutaneous dosing is specified separately.
Clinical Best Practices
- Use an FDA-authorized test to determine TMB status and apply the updated threshold of at least 13 mutations per megabase.
- Follow the applicable prescribing information for dosing and monitor for the listed warnings and treatment-limiting events.
Related Resources & Content
Based on findings from:
FDA raises TMB threshold for pembrolizumab
Mouj Hijazi. MDSpire News, 2026.
https://news.mdspire.com/internal-medicine/articles/fda-raises-tmb-threshold-for-pembrolizumab/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
